Mitjavila, Mercedes
Jimenez-Fonseca, Paula
Belló, Pilar
Pubul, Virginia
Percovich, Juan Carlos
Garcia-Burillo, Amparo
Hernando, Jorge
Arbizu, Javier
Rodeño, Emilia
Estorch, Montserrat
Llana, Belén
Castellón, Maribel
García-Cañamaque, Lina
Gajate, Pablo
Riesco, Maria Carmen
Miguel, Maria Begoña
Balaguer-Muñoz, David
Custodio, Ana
Cano, Juana María
Repetto, Alexandra
Garcia-Alonso, Pilar
Muros, Maria Angustias
Vercher-Conejero, Jose Luis
Carmona-Bayonas, Alberto http://orcid.org/0000-0002-1930-9660
Funding for this research was provided by:
Novartis Farmacéutica
Article History
Received: 6 December 2022
Accepted: 18 February 2023
First Online: 6 March 2023
Declarations
:
: The study was approved by the Research Ethics Committee of the Principality of Asturias (151/17, November 3, 2017) and by the Spanish Agency of Medicines and Medical Devices (AEMPS) as a post authorization study with prospective follow-up (PAS-PF) (identification code: CSV: DSRZJ6QF1B). All procedures followed were in accordance with the ethical standards of the committee responsible for human experimentation (institutional, local, and national) and with the Helsinki Declaration of 1964 and later versions. Informed consent was obtained from all patients before being included in the study. This study is an observational, non-interventionist trial. This work is original and has not been previously presented elsewhere.
: Not applicable.
: ACB has received travel grants and participated in advisory boards from Novartis. The other authors declare that they have no conflicts of interest in relation to the scope of this work. This is an academic study.
: The SEPTRALU registry (SEMNIM-SER-2021-01) is promoted by Spanish Society of Nuclear Medicine and Molecular Imaging (SEMNIM) in collaboration with the Spanish Society of Endocrinology and Nutrition (SEEN).